LifeVest Innovation for Better Outcomes

“It’s comfortable. It was extremely easy. People don’t even know you’re wearing it.”

-Tanya, LifeVest patient

Female LifeVest patient outside with friend

Zero median false alarms at 90 days with advanced arrhythmia discrimination (AArD)³

ZOLL® uses AI-based AArD technology to filter out non-physiological electrocardiogram (ECG) signals, reducing an already low rate of false alarms.

Research published in 2023 validates LifeVest is smarter than ever.

VIEW THE DATA ON 96,000 PATIENTS

woman looking at phone screen which is displaying LifeVest Patient App data

Education, data & support during recovery

The LifeVest Patient App helps patients get the most out of their LifeVest experience.

Track progress with access to their own Wear Time^® and Activity data.
On-demand device education, success stories, and support resources – all at your patients’ fingertips.

Learn more about the LifeVest patient app

Infographic showing that 1 in 14 patients experience an actionable arrhythmia during LifeVest use

Highly accurate, FDA-approved classification of ECGs⁶

1 in 14 patients experience an actionable arrhythmia during LifeVest use.⁷ Developed with machine learning, LifeVest ECG Classifier filters out noise and identifies arrhythmias that may require intervention — from ablation to ICD implant.

See how ECGs captured by LifeVest enabled physicians to modify their patient’s treatment path.

ECG CASE STUDIES

Infographic displaying ZOLL LifeVest's comprehensive coverage for patients

Comprehensive coverage for Medicare, Medicaid, veterans, and commercial patients

ZOLL has spent 20+ years building positive payer relationships and an extensive support network to help your patients with every step of their LifeVest journey:

A range of financial programs provide access options for uninsured and underinsured patients
The largest, most experienced WCD support team
In-person training and support from representatives with extensive care experience
24/7 multilingual support

Data on file, 20c1184_a01. Garment Comparative Wear Test.
Data on file, 90d0258_a01. 2021 Commercial Compliance Analysis.
Arkles J, Delaughter C, D’Souza B. A novel artificial intelligence based algorithm to reduce wearable cardioverter-defibrillator alarms. J Interv Cardiac Electrophysiol. 2023. https://doi.org/10.1007/s10840-023-01497-w
Olgin JE, Lee BK, Vittinghoff E, et al. Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As-treated and per-protocol analyses. J Cardiovasc Electrophysiol 2020;1–10. https://doi.org/10.1111/jce.14404
Kutyifa V, Moss A, Klein H, et al. One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry). Pacing Clin Electrophysiol. 2018;1–7. https://doi.org/10.1111/pace.13448
Pre-clinical test data on file at ZOLL as of July 2020.
Kutyifa V, Moss A J, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation 2015;132(17):1613–1619.

Innovation that delivers better outcomes

Innovations backed by real results you can count on

Next generation LifeVest garment

Preferred by patients for comfort

AI-enhanced algorithm

Zero median false alarms at 90 days with advanced arrhythmia discrimination (AArD)³

20+ years of clinical evidence

The LifeVest Patient engagement app

Education, data & support during recovery

See actionable arrhythmias with ECG Classifier

Highly accurate, FDA-approved classification of ECGs⁶

Broad WCD coverage & the largest, most experienced support team

Comprehensive coverage for Medicare, Medicaid, veterans, and commercial patients

Contact a Product Expert